Delårsrapport 1 januari – 30 september 2018
November 14, 2018 02:30 ET
|
AroCell AB
Väsentliga händelser under perioden 1 januari till 30 september AroCell ingick ett icke exklusivt licensavtal med Roche Diagnostics, ett av världens största diagnostikbolag med fokus på...
Ytterligare ett abstract som visar värdet av AroCells provberedningssteg i samband med diagnostik har accepterats av ISOBM inför mötet i Hamburg
October 09, 2018 02:40 ET
|
AroCell AB
AroCell meddelar idag att ytterligare ett abstract har accepterats av ISOBM (International Society of Oncology and BioMarkers) för presentation som poster vid organisationens årliga konferens i...
A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method
October 09, 2018 02:40 ET
|
AroCell AB
AroCell AB announces today that a second abstract has been accepted by ISOBM (International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany...
En ny studie som jämför TK 210™ ELISA med aktivitetsbaserade assays utvecklade att mäta TK1 i serum, visar en hög korrelation mellan metoderna när prover från personer med hematologiska maligniteter analyseras. Studien kommer att presentera
September 18, 2018 05:30 ET
|
AroCell AB
Ett abstract med titeln " A performance evaluation of three currently used thymidine kinase 1 assays in sera from patients with hematological malignancies shows high concordance", författat av Staffan...
A new study comparing TK 210™ ELISA from AroCell with other activity-based assays for the measurement of TK1 in serum shows high correlation between methods when samples from subjects with hematological malignancies are compared. The study
September 18, 2018 05:30 ET
|
AroCell AB
An abstract entitled “A performance evaluation of three currently used thymidine kinase 1 assays in sera from patients with hematological malignancies shows high concordance”, by Staffan Eriksson et...
New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
August 24, 2018 07:50 ET
|
AroCell AB
A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...